Glasdegib

Breastfeeding
  • TRADE NAME: Daurismo (Pfizer)
  • INDICATIONS: indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
  • CLASS: Hedgehog (Hh) signaling pathway inhibitor
  • HALF-LIFE: 17.4 hours

FDA APPROVAL DATE: 11/21/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
can cause fetal harm, not recommended for use during pregnancy

EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning

Our database has 43 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OTHER


Page last updated 11/26/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric